Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of TAK-360 in narcolepsy or idiopathic hypersomnia
2025-522833-68-01Phase 3Authorised
- Sponsor
- Takeda
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of TAK-360 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and hypersomnolence disorder, sponsored by Takeda. Primary endpoint: Occurrence of at least 1 treatment-emergent adverse event. Planned start Oct 2026; status: authorised.
02
Drugs
TAK-360
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)hypersomnolence disorder
Beyond the preview
Go deeper on 2025-522833-68-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522833-68-01.